Literature DB >> 29440335

Age- and sex-specific Canadian utility norms, based on the 2013-2014 Canadian Community Health Survey.

Jason R Guertin1, David Feeny2, Jean-Eric Tarride2.   

Abstract

BACKGROUND: Although many Canadian studies have provided disease-specific or patient group-specific utility scores, the utility score norms currently available for the general Canadian population are outdated. Canadian guideline recommendations for the economic evaluation of health technologies advocate for utilities reflecting those of the general population and for stratified analyses when results are heterogeneous; as such, there is also a need for age-, sex- and jurisdiction-specific utility score norms.
METHODS: We used data from the 2013-2014 Canadian Community Health Survey. We used the Health Utilities Index Mark 3 to calculate utility scores. We estimated means (with 95% confidence intervals [CIs]) and medians (with interquartile ranges [IQRs]) for utility scores. In addition to Canadian-level measures, we stratified all utility score norms by respondents' age, sex, and province or territory of residence. We weighted respondents' answers and computed 95% CIs using sampling weights and bootstrap weights provided by Statistics Canada to extrapolate the study findings to the Canadian population.
RESULTS: Respondents to the 2013-2014 Canadian Community Health Survey represented 30 014 589 community-dwelling Canadians 12 years of age and older (98% of the Canadian population); half of the respondents were female (50.6%), and the weighted average age was 44.8 (95% CI 44.7-44.9) years. The mean and median self-reported utility scores for Canadians were estimated at 0.863 (95% CI 0.861-0.865) and 0.927 (IQR 0.838-0.972), respectively.
INTERPRETATION: This study provides utility score norms for several age-, sex-and jurisdiction-specific strata in Canada. These results will be useful for future cost-utility analyses and could serve as benchmark values for comparisons with future studies.
© 2018 Joule Inc. or its licensors.

Entities:  

Mesh:

Year:  2018        PMID: 29440335      PMCID: PMC5809215          DOI: 10.1503/cmaj.170317

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  25 in total

Review 1.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

2.  Multiattribute and single-attribute utility functions for the health utilities index mark 3 system.

Authors:  David Feeny; William Furlong; George W Torrance; Charles H Goldsmith; Zenglong Zhu; Sonja DePauw; Margaret Denton; Michael Boyle
Journal:  Med Care       Date:  2002-02       Impact factor: 2.983

Review 3.  Valuing health States for use in cost-effectiveness analysis.

Authors:  John Brazier
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Utility scores for chronic conditions in a community-dwelling population.

Authors:  N Mittmann; K Trakas; N Risebrough; B A Liu
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

5.  Comparing population health in the United States and Canada.

Authors:  David Feeny; Mark S Kaplan; Nathalie Huguet; Bentson H McFarland
Journal:  Popul Health Metr       Date:  2010-04-29

6.  The predictive validity of health-related quality of life measures: mortality in a longitudinal population-based study.

Authors:  Mark S Kaplan; Jean-Marie Berthelot; David Feeny; Bentson H McFarland; Saeeda Khan; Heather Orpana
Journal:  Qual Life Res       Date:  2007-11       Impact factor: 4.147

7.  US norms for six generic health-related quality-of-life indexes from the National Health Measurement study.

Authors:  Dennis G Fryback; Nancy Cross Dunham; Mari Palta; Janel Hanmer; Jennifer Buechner; Dasha Cherepanov; Shani A Herrington; Ron D Hays; Robert M Kaplan; Theodore G Ganiats; David Feeny; Paul Kind
Journal:  Med Care       Date:  2007-12       Impact factor: 2.983

8.  The burden of Parkinson disease (PD) and concomitant comorbidities.

Authors:  Sheri L Pohar; C Allyson Jones
Journal:  Arch Gerontol Geriatr       Date:  2009-01-08       Impact factor: 3.250

Review 9.  A review of health utilities across conditions common in paediatric and adult populations.

Authors:  Jean-Eric Tarride; Natasha Burke; Matthias Bischof; Robert B Hopkins; Linda Goeree; Kaitryn Campbell; Feng Xie; Daria O'Reilly; Ron Goeree
Journal:  Health Qual Life Outcomes       Date:  2010-01-27       Impact factor: 3.186

10.  A comparison of health utility scores calculated using United Kingdom and Canadian preference weights in persons with alzheimer's disease and their caregivers.

Authors:  Mingying Fang; Mark Oremus; Jean-Eric Tarride; Parminder Raina
Journal:  Health Qual Life Outcomes       Date:  2016-07-18       Impact factor: 3.186

View more
  11 in total

1.  Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD.

Authors:  Kate M Johnson; Mohsen Sadatsafavi; Amin Adibi; Larry Lynd; Mark Harrison; Hamid Tavakoli; Don D Sin; Stirling Bryan
Journal:  Appl Health Econ Health Policy       Date:  2020-11-02       Impact factor: 2.561

2.  Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2022-08-23

3.  Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2022-04-01

4.  Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.

Authors:  William K Evans; Cindy L Gauvreau; William M Flanagan; Saima Memon; Jean Hai Ein Yong; John R Goffin; Natalie R Fitzgerald; Michael Wolfson; Anthony B Miller
Journal:  CMAJ Open       Date:  2020-09-22

5.  Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.

Authors:  T Younis; A Lee; M E Coombes; N Bouganim; D Becker; C Revil; G S Jhuti
Journal:  Curr Oncol       Date:  2020-12-01       Impact factor: 3.677

6.  Japanese health utilities index mark 3 (HUI3): measurement properties in a community sample.

Authors:  Shinichi Noto; Takamoto Uemura
Journal:  J Patient Rep Outcomes       Date:  2020-01-29

7.  Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada.

Authors:  Cynthia Mbuya Bienge; Nora Pashayan; Jennifer D Brooks; Michel Dorval; Jocelyne Chiquette; Laurence Eloy; Annie Turgeon; Laurence Lambert-Côté; Jean-Sébastien Paquette; Emmanuelle Lévesque; Julie Hagan; Meghan J Walker; Julie Lapointe; Gratien Dalpé; Palmira Granados Granados Moreno; Kristina Blackmore; Michael Wolfson; Yann Joly; Mireille Broeders; Bartha M Knoppers; Anna M Chiarelli; Jacques Simard; Hermann Nabi
Journal:  J Pers Med       Date:  2021-02-02

8.  Estimating the population health burden of Lyme disease in Ontario, Canada: a microsimulation modelling approach.

Authors:  Stephen Mac; Gerald A Evans; Samir N Patel; Eleanor M Pullenayegum; Beate Sander
Journal:  CMAJ Open       Date:  2021-11-16

9.  Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.

Authors:  Ron Goeree; Natasha Burke; Manon Jobin; Jacques P Brown; Donna Lawrence; Björn Stollenwerk; Damon Willems; Ben Johnson
Journal:  Arch Osteoporos       Date:  2022-04-26       Impact factor: 2.879

10.  The OncoSim-Breast Cancer Microsimulation Model.

Authors:  Jean H E Yong; Claude Nadeau; William M Flanagan; Andrew J Coldman; Keiko Asakawa; Rochelle Garner; Natalie Fitzgerald; Martin J Yaffe; Anthony B Miller
Journal:  Curr Oncol       Date:  2022-03-03       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.